Phase Ib study of PRT543, an oral protein arginine methyltransferase 5 (PRMT5) inhibitor, in patients with advanced splicing factor-mutant myeloid malignancies.
Bewersdorf JP, Mi X, Lu B, Kuykendall A, Sallman D, Patel M, Stevens D, Philipovskiy A, Sutamtewagul G, Masarova L, Keiffer G, Verma A, Bhagwat N, Wang M, Moore A, Rager J, Heiser D, Ro S, Hong WJ, Abdel-Wahab O, Stein EM.
Bewersdorf JP, et al. Among authors: mi x.
Leukemia. 2025 Jan 24. doi: 10.1038/s41375-025-02515-8. Online ahead of print.
Leukemia. 2025.
PMID: 39856223
No abstract available.